| scholarly article | Q13442814 |
| P2093 | author name string | Philippe Rizek | |
| James R Perry | |||
| Rosemary Cashman | |||
| Tara Morrison | |||
| Meredith Morrison | |||
| P2860 | cites work | MGMT gene silencing and benefit from temozolomide in glioblastoma | Q27824832 |
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Diagnosis and treatment of recurrent high-grade astrocytoma | Q31033873 | ||
| Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules | Q33347264 | ||
| Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications | Q33358579 | ||
| The anti-angiogenic basis of metronomic chemotherapy | Q35788112 | ||
| Canadian recommendations for the treatment of glioblastoma multiforme. | Q35855352 | ||
| Salvage temozolomide for prior temozolomide responders | Q36306363 | ||
| Targeted modulation of MGMT: clinical implications | Q36374670 | ||
| Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. | Q40143844 | ||
| Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens | Q40177895 | ||
| Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials | Q44571546 | ||
| Response criteria for phase II studies of supratentorial malignant glioma | Q44781447 | ||
| Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity | Q46712987 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | temozolomide | Q425088 |
| P304 | page(s) | 2152-2157 | |
| P577 | publication date | 2008-10-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach | |
| P478 | volume | 113 |
| Q33391296 | A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. |
| Q36143344 | A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy |
| Q38014949 | Advances in malignant glioma drug discovery |
| Q37528441 | Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. |
| Q33396384 | Bevacizumab and daily temozolomide for recurrent glioblastoma |
| Q38068203 | Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date |
| Q35821404 | Cellular-based immunotherapies for patients with glioblastoma multiforme. |
| Q34014740 | Central nervous system cancers |
| Q38438439 | Chemotherapy in glioma |
| Q37696867 | Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients |
| Q34418437 | Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations |
| Q37904921 | Current concepts and management of glioblastoma |
| Q34186787 | Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study. |
| Q37766550 | Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects |
| Q35967416 | Drug rechallenge and treatment beyond progression--implications for drug resistance. |
| Q30616602 | Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors |
| Q39274632 | Drug therapy of patients with recurrent glioblastoma: is there any evidence? |
| Q35008709 | Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma |
| Q33406919 | Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma |
| Q39356631 | Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines |
| Q33392078 | Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma |
| Q26784500 | Environmental Epigenetics: Crossroad between Public Health, Lifestyle, and Cancer Prevention |
| Q37952240 | Evolution of care for patients with relapsed glioblastoma. |
| Q37862235 | Evolving strategies: future treatment of glioblastoma |
| Q38542100 | Extracranial metastasis of gliobastoma: Three illustrative cases and current review of the molecular pathology and management strategies |
| Q33382912 | Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). |
| Q33932427 | Glioblastoma: patterns of recurrence and efficacy of salvage treatments |
| Q33393291 | Immature and absolute platelet count changes and thrombocytopenia in malignant glioma |
| Q58760084 | In vitro effect of chlorambucil on human glioma cell lines (SF767 and U87-MG), and human microvascular endothelial cell (HMVEC) and endothelial progenitor cells (ECFCs), in the context of plasma chlorambucil concentrations in tumor-bearing dogs |
| Q37027202 | Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts |
| Q33416019 | Intra-arterial carboplatin as a salvage strategy in the treatment of recurrent glioblastoma multiforme |
| Q55461270 | Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma: final report of a pilot study. |
| Q37649471 | MGMT promoter methylation in malignant gliomas: ready for personalized medicine? |
| Q40867629 | Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis |
| Q37763502 | Metronomic chemotherapy: new rationale for new directions |
| Q99553463 | Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide |
| Q41450286 | Perspectives of Medical Specialists on Sharing Decisions in Cancer Care: A Qualitative Study Concerning Chemotherapy Decisions With Patients With Recurrent Glioblastoma |
| Q37727000 | Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma |
| Q36201411 | Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas |
| Q35788884 | Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma |
| Q35008766 | Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy |
| Q33388306 | Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma |
| Q33384898 | Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma |
| Q42579518 | Reply to M.C. Chamberlain |
| Q35869497 | Retrospective analysis of bevacizumab in combination with ifosfamide, carboplatin, and etoposide in patients with second recurrence of glioblastoma |
| Q36542980 | Role of Biomarkers in the Clinical Management of Glioblastomas: What are the Barriers and How Can We Overcome Them? |
| Q38647190 | Temozolomide alone or in combination with doxorubicin as a rescue agent in 37 cases of canine multicentric lymphoma |
| Q42426015 | Temozolomide and MGMT forever? |
| Q37995906 | Temozolomide dosing regimens for glioma patients |
| Q86854179 | The Role of Radiation Therapy in Gross Totally Resected Meningiomas |
| Q38579564 | The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis |
| Q38205133 | The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline |
| Q43075079 | Tonsillar pseudotumor: complications of chronically-administered temozolomide |
| Q39045968 | Treatment options for recurrent high-grade gliomas |
Search more.